A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both BRCA mutant (mut) and BRCA wildtype (wt) adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers who have demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Kaiming, Mikule, Keith, Wang, Zebin, Poon, Grace, Vaidyanathan, Aparajitha, Smith, Gillian, Zhang, Zhi-Yi, Hanke, Jeffrey, Ramaswamy, Sridhar, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324689/
https://www.ncbi.nlm.nih.gov/pubmed/30647846
http://dx.doi.org/10.18632/oncotarget.26354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324689/
https://www.ncbi.nlm.nih.gov/pubmed/30647846
http://dx.doi.org/10.18632/oncotarget.26354

Ejemplares similares